A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adult

Sponsor:

ECOG-ACRIN Cancer Research Group

Sponsor Study ID:

EA9181

CTO #:

103770

NCT Number:

NCT04530565

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lymphoid Leukemia

Study Objectives:

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)